Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. - Wikidata - wikimedia - TriplyDB

Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.

Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.

http://www.wikidata.org/entity/Q34097560

about

Immune and non-immune responses to hepatitis C virus infection Neutralizing antibody response to hepatitis C virus Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein Structural evidence for a bifurcated mode of action in the antibody-mediated neutralization of hepatitis C virus Discrete conformations of epitope II on the hepatitis C virus E2 protein for antibody-mediated neutralization and nonneutralization A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design Optimization of peptide arrays for studying antibodies to hepatitis C virus continuous epitopes.Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies.A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.Designing and Development of a DNA Vaccine Based On Structural Proteins of Hepatitis C Virus Induction of broadly neutralising HCV antibodies in mice by integration-deficient lentiviral vector-based pseudotyped particles Will there be a vaccine to prevent HCV infection?Antigenic cooperation among intrahost HCV variants organized into a complex network of cross-immunoreactivity.Hepatitis C virus infection: establishment of chronicity and liver disease progression Structure of Hepatitis C Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody IGH526.Immunoglobulin with High-Titer In Vitro Cross-Neutralizing Hepatitis C Virus Antibodies Passively Protects Chimpanzees from Homologous, but Not Heterologous, Challenge Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine-induced neutralizing activity Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function.The novel replication-defective vaccinia virus (Tiantan strain)-based hepatitis C virus vaccine induces robust immunity in macaques Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development.Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen.Prospects for prophylactic hepatitis C vaccines based on virus-like particles Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.Complete definition of immunological correlates of protection and clearance of hepatitis C virus infection: a relevant pending task for vaccine development.Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies.Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles.Progress in the development of vaccines for hepatitis C virus infection.Amino acid residue-specific neutralization and nonneutralization of hepatitis C virus by monoclonal antibodies to the E2 protein.Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains.A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques.A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles.Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus.Hepatitis C virus E2 envelope glycoprotein induces an immunoregulatory phenotype in macrophages.The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein.Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.Hepatitis C Vaccines, Antibodies, and T Cells.

P2860

Q26782040-9B7D81EE-4D24-4E00-9FC1-FEFDCEC6378D Q27027484-461EDB42-F02E-432E-8E9B-8B1102664357 Q27333881-607382DD-66C0-4DE8-81B0-A92C68DA3E9D Q27677400-972A21E0-3403-422D-940B-4B7C91D5A1DA Q27684579-22EF1066-7453-4CD5-A05B-8B6D9BF44119 Q28488268-DFBA8999-913B-4A51-B913-0723AFD954D6 Q30374314-3AC6351C-8527-45AD-9172-E43B562E86D6 Q33563569-4520CA66-EB06-4EDE-9C4C-5B88BF6C08A4 Q33602744-A1586123-7C94-4426-A172-FF03E92FB60D Q33890011-AC3EE6DF-838A-4648-BE9A-2C39345496FA Q34009510-9C3C7C38-090F-471F-AF03-09CCD4703D55 Q34262165-22B605AF-D588-42B4-93B8-4083A1D249C5 Q34543833-76C72E90-D577-4AA6-8F3C-F592BF0596A6 Q34693362-882690E0-ED77-4114-85E6-C576C9C3A7F8 Q34781537-85894DAB-48FC-42B9-AAC3-48184846429E Q35669397-295FEF2E-2812-436E-A36F-9E8F1DA7F341 Q35728873-1E5BCA64-4B8D-45B2-8BB1-47C67126AAA0 Q35912053-BD28C61E-6A99-4A22-9C28-AA9ACAD7E77B Q35913863-A64332EE-0696-44D5-B835-387EA1798F0D Q36363203-A1DD3F96-2131-4950-A755-4EB44D547724 Q36378193-78E43367-5E6D-4E1A-8603-0B30FD0030EA Q36827324-C2A2F555-EAD8-48E3-9675-4B7A616B8D87 Q37181386-968BC405-7A5B-4339-9B3E-9EC77185D49D Q37354049-C9AB1712-16D8-47C0-AC99-A4847761893A Q37417839-C1096739-AA29-4A4F-A0EF-53F98F794252 Q37505405-3033C736-2BFF-41C8-ABB8-7259071C7641 Q37512845-31FDEF4F-0C76-42DA-B9EC-D62229099DC6 Q38010203-7C4C34E3-F274-4536-B1BB-6715F200D7FC Q38234934-0030C8A1-7C14-4C0F-889B-940CEA28D0CE Q38315657-D5B7EAA9-8E9F-4022-8480-33DAAFCCBA8C Q38635596-90FA48E6-F904-45DF-9A8A-AC4EE3D67952 Q41168118-3ACE212A-B84F-4E57-838F-67C3E452EBF4 Q42951318-9EB12D0A-1C51-4E7C-9128-FF0F932126C4 Q43039402-512BCDD2-1586-4D21-8A1F-0991DEAA9AA6 Q45362011-638B5F4E-5AFF-48B2-9404-371B3C47F39B Q47548062-6CC9A2BB-09E1-4013-AE77-DCD1EA8B1447 Q50005891-76C8B47F-E4CF-460E-8892-029553FDF7F9 Q55299977-AFEAFA00-645C-4FEB-B01A-3F83825BDE07 Q55385159-7F94630B-78E6-4CD4-98A2-D68DA97838AA Q55709137-9657E2B8-B48D-418B-97C6-E32EE3C3703A

P2860

Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.

http://www.wikidata.org/entity/Q34097560

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Characterization of antibodies ...... virus envelope glycoproteins.

@ast

Characterization of antibodies ...... virus envelope glycoproteins.

@en

Characterization of antibodies ...... virus envelope glycoproteins.

@nl

type

label

Characterization of antibodies ...... virus envelope glycoproteins.

@ast

Characterization of antibodies ...... virus envelope glycoproteins.

@en

Characterization of antibodies ...... virus envelope glycoproteins.

@nl

prefLabel

Characterization of antibodies ...... virus envelope glycoproteins.

@ast

Characterization of antibodies ...... virus envelope glycoproteins.

@en

Characterization of antibodies ...... virus envelope glycoproteins.

@nl

P1433

Q34097560-9EBB25EC-68C8-4F0E-8E0B-F2D460494A67

P1476

Q34097560-12536794-DCA0-4EC1-8035-7148C484D808

P2093

Q34097560-246FACAB-0FF8-4D50-9CD5-7841054A98FC

Q34097560-8A5AC1AC-D922-4F69-98B0-1CC673205149

Q34097560-8F5FDAB5-0B45-4627-B05A-850865E28780

Q34097560-AFA675E2-779D-41C3-A5ED-50F2E788745C

Q34097560-DBD68F6D-63CF-49D8-9D6F-600AAD68618B

Q34097560-E603C148-2BCA-4AE1-93A6-7B66654F8499

P2860

Q34097560-055EC4C7-F80C-4F3B-B5B8-C467F908E3AE

Q34097560-099491CA-98F1-4E69-8EB2-348B97F3AB76

Q34097560-0FF8D1CC-F54A-408E-962D-253E530AC9BF

Q34097560-24F31242-E6E6-44EA-ABB8-1BF159FD5584

Q34097560-2A281B08-48B7-4540-A8C2-F2E0838C9B0C

Q34097560-2D4E3AAF-F9F0-48DF-A9AD-8183021C292A

Q34097560-3788B0CA-B1DF-4F52-B762-D4F3826D8F1F

Q34097560-6B3E6ED7-9D2A-4F4C-A2F3-DC595511B2B9

Q34097560-6C40261E-F376-49C0-A660-48C339385CCA

Q34097560-84777C53-B40A-4AE2-A59F-A4F4B2EB438E

P304

Q34097560-6A1E120C-3B3F-466E-A606-9DE08FAF4098

P31

Q34097560-684C2971-E23A-4B3D-8D5B-DA24B3642A8E

P356

Q34097560-FC98AF59-6338-4530-8B2F-A4D6AE62D99A

P407

Q34097560-93B912A7-580F-4863-B88C-5F0257ECAAF8

P433

Q34097560-080571AA-76F7-4098-82B1-379D958EACFA

P478

Q34097560-B9B627DC-3768-4E2B-B5F6-4AF5C8504545

P50

Q34097560-0B109B4F-86A2-4C37-9087-102C85AD5C21

Q34097560-11583247-CA8D-4E9A-8B49-F85944BEF5C6

Q34097560-D6F7A9AE-BB44-4998-83F8-70B427907178

P577

Q34097560-72FE5CC1-8C02-463E-870C-88A15898DC6B

P5875

Q34097560-6C1E9B37-C617-4B08-A920-637F9179250D

P698

Q34097560-E7EA0773-B5F7-4C7B-8AF5-6C23DAE38848

P921

Q34097560-4AF672E3-85F5-47C1-92C4-A47EAA745F06

P932

Q34097560-07719962-9E89-4983-8A76-B7CA3D230B65

P356

P1433

The Journal of Infectious Diseases

P1476

Characterization of antibodies ...... C virus envelope glycoproteins

@en

P2093

Arnab Basu

http://www.w3.org/2001/XMLSchema#string

Keith Meyer

http://www.w3.org/2001/XMLSchema#string

Michael Houghton

http://www.w3.org/2001/XMLSchema#string

Ranjit Ray

http://www.w3.org/2001/XMLSchema#string

Sharon E Frey

http://www.w3.org/2001/XMLSchema#string

Stephen Coates

http://www.w3.org/2001/XMLSchema#string

P2860

Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus

Generation of Infectious Hepatitis C Virus in Immortalized Human Hepatocytes

Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles

Isolation and Characterization of Broadly Neutralizing Human Monoclonal Antibodies to the E1 Glycoprotein of Hepatitis C Virus

Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus

Vaccination of chimpanzees against infection by the hepatitis C virus

Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections

Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.

Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity.

Coexpression of hepatitis C virus E1 and E2 chimeric envelope glycoproteins displays separable ligand sensitivity and increases pseudotype infectious titer.

P304

862-866

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/655902

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

202

http://www.w3.org/2001/XMLSchema#string

P50

Sergio Abrignani

Robert B Belshe

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45460122

http://www.w3.org/2001/XMLSchema#string

P698

20677942

http://www.w3.org/2001/XMLSchema#string

P921

P932

2931414

http://www.w3.org/2001/XMLSchema#string